60) s that they represent early events during tumor progression and additional alteratio |
61) atterns have been shown to correlate with tumor progression and metastasis. |
62) functional role of SAA1 polymorphisms in tumor progression and to investigate the r |
63) rant ANG levels promote specific steps in tumor progression are unknown. |
64) Local progression was defined as tumor progression by imaging, or if other |
65) titative optical biomarkers of epithelial tumor progression by use of nonlinear opti |
66) n factor CUX1 as an important mediator of tumor progression in PDAC. |
67) s triggers inflammation and thus promotes tumor progression in a cell non-autonomous |
68) thermore, its expression increased during tumor progression in a genetic mouse model |
69) n higher stage tumors and correlated with tumor progression in breast cancer patient |
70) iRNAs) are involved in carcinogenesis and tumor progression in non-small-cell lung c |
71) d that B[a]PDE induced phosphorylation of tumor progression locus 2 (Tpl2), a direct |
72) and functions as a positive regulator in tumor progression of androgen-independent |
73) MTC, and additional p53 loss led to rapid tumor progression. |
74) link between inflammation and metastatic tumor progression. |
75) ency of recurrence and, in certain cases, tumor progression. |
76) sed apoptosis that had to be overcome for tumor progression. |
77) insic indicator for evaluating epithelial tumor progression. |
78) zation and inhibition of angiogenesis and tumor progression. |
79) plays an important role during epithelial tumor progression. |
80) serve as a link between inflammation and tumor progression. |
81) 1.4 months after SBRT with no evidence of tumor progression. |
82) inhibit the release of certain cytokines (tumor necrosis factor-α, interleukin-1β, |
83) Anti-tumor necrosis factor (anti-TNF) biologics |
84) Tumor necrosis factor-α (TNF-α), interle |
85) pond to methotrexate, treatment with anti-tumor necrosis factor (TNF)-α is an optio |
86) ing biochemical parameters were measured: tumor necrosis factor (TNF), interleukin-1 |
87) nstillation caused dose-trend increase in tumor necrosis factor alpha (TNF-α), inte |
88) ecretion of the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) from h |
89) lial fibrillary acidic protein (GFAP) and tumor necrosis factor alpha (TNFα) levels |
90) e 34.55 ± 16.30 years) refractory to tumor necrosis factor blockers and standar |
91) Management of tumor necrosis factor receptor-associated |
92) e (NO), lung interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), hydr |
|